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ttp://dx.doi.org/10.1016/j.ajpath.2014.11.006Small animal models of chronic obstructive pulmonary disease (COPD) have several limitations for iden-
tifying new therapeutic targets and biomarkers for human COPD. These include a pulmonary anatomy that
differs from humans, the limited airway pathologies and lymphoid aggregates that develop in smoke-
exposed mice, and the challenges associated with serial biological sampling. Thus, we assessed the utility
of cigarette smoke (CS)eexposed cynomolgus macaque as a nonhuman primate (NHP) large animal model
of COPD. Twenty-eight NHPs were exposed to air or CS 5 days per week for up to 12 weeks. Bronchoalveolar
lavage and pulmonary function tests were performed at intervals. After 12 weeks, we measured airway
pathologies, pulmonary inﬂammation, and airspace enlargement. CS-exposed NHPs developed robust
mucus metaplasia, submucosal gland hypertrophy and hyperplasia, airway inﬂammation, peribronchial
ﬁbrosis, and increases in bronchial lymphoid aggregates. Although CS-exposed NHPs did not develop
emphysema over the study time, they exhibited pathologies that precede emphysema development,
including increases in the following: i) matrix metalloproteinase-9 and proinﬂammatory mediator levels in
bronchoalveolar lavage ﬂuid, ii) lung parenchymal leukocyte counts and lymphoid aggregates, iii) lung
oxidative stress levels, and iv) alveolar septal cell apoptosis. CS-exposed NHPs can be used as a model of
airway disease occurring in COPD patients. Unlike rodents, NHPs can safely undergo longitudinal sampling,
which could be useful for assessing novel biomarkers or therapeutics for COPD. (Am J Pathol 2015, 185:
741e755; http://dx.doi.org/10.1016/j.ajpath.2014.11.006)Supported by the Brigham and Women’s Hospital-Lovelace Respiratory
Research Institute Research Consortium (Y.T. and C.A.O.), NIH grants P50
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Disclosures: None declared.Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality worldwide.1,2 COPD is
characterized by airﬂow limitation that is not fully reversible
and associatedwith abnormal pulmonary inﬂammation induced
by noxious particles and gases most commonly present in
cigarette smoke (CS).
Mice are widely used to investigate the biological path-
ways that contribute to lung pathologies occurring in CS-
induced COPD and to test the efﬁcacy of novel therapies for
COPD.3 Mice exposed to CS for 6 months exhibit some
features of human COPD, including chronic pulmonary
inﬂammation, modest airspace enlargement, and mild small
airway ﬁbrosis.3 The use of mice to model COPD has
several advantages, including the following: i) opportunities
for genetic manipulation and the availability of molecularstigative Pathology.
.reagents to probe changes in pathways in vivo, ii) rapid
breeding rate, and iii) small size, which is advantageous for
dosing expensive drugs. However, murine COPD models
have several limitations. In contrast to humans, mice lack
bronchial submucosal glands, clearly deﬁned respiratory
bronchioles, and a distinct lobular architecture.4 Mice also
have a monopodial airway branching pattern, rather than the
Polverino et aldichotomous pattern found in humans.5 Moreover, there are
differences in the innate and adaptive immune systems6 and
in the expressed proﬁles of matrix metalloproteinases
(MMPs) in humans versus mice.7 In mice, it is also chal-
lenging to perform serial sampling in blood or lungs to
measure biomarkers of CS-induced lung injury or responses
to therapies. Furthermore, mice do not develop robust
airway pathologies, including mucus hypersecretion and
small airway ﬁbrosis, when exposed chronically to CS.
Also, several therapies, including an anti-tumor necrosis
factor a antibody,8 roﬂumilast,9 simvastatin,10 and antioxi-
dants11 that have effectively treated emphysema in mice,
were substantially less effective when tested in COPD
patients,7,12e14 raising the issue about the utility of smoke-
exposed mice for testing novel therapeutics for the human
disease. Smoke-exposed guinea pigs have been used as an
alternative to mice as a small animal model of COPD but
have several disadvantages, including the lack of availabil-
ity of commercially available reagents for interrogating
pathways in guinea pigs.15 Thus, there is a need for alter-
native animal models that better recapitulate the physio-
logical and pathological changes occurring in the lungs of
human COPD patients.
Other models for studying disease pathogenesis and pre-
clinical testing of pharmaceuticals have been established in
larger animals.5,16 Among these, nonhuman primates (NHPs)
have great potential because their pulmonary anatomy and
immune system are similar to those of humans. Also, NHP
and human proteins have a high degree of homology, and
molecular reagents used in studies of human samples often
can be used to probe pathways in NHP samples.17
When challenged with allergens, NHPs develop allergic
airway inﬂammation, hyperresponsiveness, and extensive
airway remodeling pathologies resembling that which occurs
in human asthmatics.5 In addition, exposing NHPs to ozone
produces a persistent chronic respiratory bronchiolitis18
similar to that occurring in human smokers.19 However, to
our knowledge, there have been no prior reports of the effects
of CS exposure on the NHP lung.We hypothesized that when
exposed to CS, NHPs would develop pathological and
functional changes in their lungs similar to those occurring in
the airways of COPD patients. To test this hypothesis, we
evaluated the airway and alveolar pathologies and lung
physiology in cynomolgus macaques (Macaca fascicularis)
exposed to air or CS for up to 12 weeks. Some results have
been presented in abstract form.20
Materials and Methods
Animals
All cynomolgus macaque (M. fascicularis) NHPs were female,
with an average age of 11 years  SD 1 year and an average
weight of 3.2  SD 0.37 kg. All animals studied were female
because women who smoke have a higher risk of developing
COPD than men regardless of smoking level or intensity.21742Also, female mice develop more severe airspace enlargement
than male mice when exposed to the same dose of CS for the
same duration.22
Care of the animals complied with the regulations of the US
Department of Agriculture guidelines on the protection of
animals and the NIH’s Guide for the Care and Use of Labo-
ratory Animals23 used for scientiﬁc purposes. All experiments
conducted on NHPs were approved by our Institutional Ani-
mal Care and Use Committee. The NHPs were socially housed
(up to two animals per cage) in the Primate Facility at the
Lovelace Respiratory Research Institute (Albuquerque, NM),
in accordance with the Guide for Laboratory Animal Practice
under the Association for the Assessment and Accreditation
for Laboratory Animal Care Internationaleapproved animal
environmental conditions. The animal facility maintained a
12-hour light cycle. NHPs were exposed to 100% freshly
ﬁltered air with 10 to 15 air changes per hour in the control and
CS exposure group before initiating the exposures. Room
temperature and relative humidity were maintained according
to the Guide for the Care and Use of Laboratory Animals.23
NHPs were observed a minimum of twice daily for any sign
of illness. NHPswere fed twice daily with water available at all
times. Animals were weighed during each physical examina-
tion or collection period until necropsy.
CS Exposures
NHPs were placed into H2000 whole body exposure cham-
bers and exposed to CS [250 mg/m3 total suspended partic-
ulate matter (TPM)] for 6 hours per day, 5 days per week,
because this exposure protocol is most commonly used to
model COPD in small animals, including mice.24e26 We
used an initial CS concentration of 100 mg/m3 TPM to
acclimatize the animals to CS, and then we increased it to the
target concentration of 250 mg/m3 TPM during the ﬁrst 5
exposure days. These target CS exposure levels (100 and 250
mg/m3 TPM) were selected to simulate a heavy human
smoking pattern. For a 3000-g primate inhaling an average
volume of 800 mL/minute, a pulmonary TPM deposition of
20%, and a lung weight of 10 g, the weekly deposition of
smoke particles would be approximately 2.9 or 7.2 TPM
deposited per gram of lung per week, as was calculated
previously.27 Assuming that a human smoker with 20 ciga-
rettes per day over 1 week will have 1.8 mg TPM deposited
per gram of lung per week, the 100 and 250 mg/m3 TPM CS
dose for NHPs is similar to that of humans smoking
approximately 1.8 or 4 packs per day, respectively.
Time Points for Serial Sampling
Two different studies were performed. In the ﬁrst experi-
ment, NHPs were exposed to CS (nZ 8) or air (nZ 4) for
4 weeks in H2000 whole-body inhalation chambers for 6
hours per day, 5 days per week, to determine whether this
exposure results in signiﬁcant increases in pulmonary
inﬂammation and/or mucus metaplasia in airway epithelia.ajp.amjpathol.org - The American Journal of Pathology
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were performed at baseline before CS exposures were initi-
ated and after 1 and 4 weeks, and lung tissue was obtained at
necropsy (Table 1).
In the second experiment, NHPs were exposed to CS
(n Z 8) or air (n Z 8) for 12 weeks in H2000 whole-body
inhalation chambers for 6 hours per day, 5 days per week, to
determine whether airway and/or airspace pathologies develop
in the animals. Physical examination, pulmonary function tests
(PFTs), and BAL were performed at baseline and after 4 and
12 weeks, and lung tissue was obtained at necropsy (Table 1).
Exposures >12 weeks were not feasible because of the high
costs associated with husbandry, performing the exposures,
and sample collections.PFT
PFT was performed on NHPs exposed to air or CS for 12
weeks (n Z 8 animals per group) using a whole-body ﬂow
plethysmography constructed and operated as described pre-
viously for dogs.28 The animals were anesthetized with 2% to
3% isoﬂurane and intubated, an esophageal catheter was
inserted, and the animals were placed supine in the plethys-
mograph. The endotracheal tube was attached to an airway
port, and the distal end of the esophageal catheter was passed
through a small opening located near the airway port. The
esophageal catheter was connected to a differential pressure
transducer that was vented to the airway for measurement of
transpulmonary pressure. A valve system allowed the airway
to be connected to positive and negative pressure reservoirs for
induction of inspiration and expiration. The data collectionTable 1 Design of the 4- and 12-Week CS versus Air Exposure
Experiment
Exposure time points Procedures performed
4-Week exposure
Baseline Physical examination, (BAL) on 12 NHPs
1 Week All animals: physical examination and BAL
on eight CS-exposed and four air-
exposed NHPs
4 Weeks End CS exposures on CS animals
All animals: physical examination, BAL, and
lung tissue collection on eight CS-
exposed and four air-exposed NHPs
12-Week exposure
Baseline Physical examination, BAL, and PFTs on 16
NHPs
4 Weeks All animals: physical examination, BAL,
and PFTs on eight CS-exposed and eight
air-exposed NHPs
12 Weeks End CS exposures on CS animals
All animals: physical examination, BAL,
PFTs, and lung tissue collection on eight
CS-exposed and eight air-exposed NHPs
BAL, bronchoalveolar lavage; CS, cigarette smoke; NHP, nonhuman pri-
mate; PFT, pulmonary function test.
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was adjusted to maximize the transpulmonary pressure trace.
Anesthesia was maintained at a light surgical plane for the
duration of testing. During apnea induced by brief hyperven-
tilation, the airway was connected to the positive pressure
reservoir through a valve that provided a slow inspiration to
total lung capacity, deﬁned as a transpulmonary pressure of 30
cm H2O. The pressure-volume trace was recorded during
quasistatic expiration (5 seconds), and the quasistatic chord
compliance was measured as the slope between 10 cm H2O
and functional residual capacity (relaxed lung volume). After a
period of spontaneous respiration, the hyperventilation-
inspiration sequence was repeated, followed by evacuation
of the lung to the negative pressure reservoir without inten-
tional limitation of ﬂow. The forced vital capacity, the per-
centage of forced vital capacity exhaled in 0.1 seconds, and the
peak expiratory ﬂow were measured during this forced
expiration.
BAL
Bronchoscopy, followed by BAL, was performed at baseline
and after 1, 4, and/or 12 weeks of exposure to CS or air
(Table 1). Animals were sedated with 5 to 10 mg/kg ketamine
(delivered by the i.m. route) and anesthetized with inhaled
isoﬂurane delivered using a mask. An endotracheal tube of an
appropriate size for the animal was placed into the animal’s
trachea. A bronchoscope (model BF-3C40; Olympus
America Inc., Melville, NY) was maneuvered through the
endotracheal tube and wedged in approximately a fourth- to
sixth-generation airway in the right diaphragmatic lung lobe.
Two 10-mL aliquots of sterile USP-grade endotoxin-free
saline were instilled and aspirated in succession, followed by
further aspiration with an empty syringe to recover as much
BAL ﬂuid (BALF) as possible, which was frozen to 80C
for subsequent analyses.
Pulmonary Inﬂammation Measured in BAL Samples
All leukocytes, macrophages, polymorphonuclear neutro-
phils (PMNs), and lymphocytes were counted in BAL sam-
ples from air- and CS-exposed NHPs (four air- and eight
CS-exposed NHPs in the 4-week exposure experiment and
eight NHPs per group in the 12-week exposure experiment).
IL-6, chemokine (C-X-C motif) ligand 8 (CXCL8), and
chemokine (C-X-C motif) ligand 2 (CCL2) levels were
measured in BALF from air- and CS-exposed NHPs (eight
animals per group) using the Milliplex multi-analyte panels
NHP cytokine Luminex multiplex assay (EMD Millipore,
Billerica, MA). MMP-9 levels were measured in BALF
samples using a human Duoset MMP-9 enzyme-linked
immunosorbent assay kit (R&D Systems,Minneapolis, MN).
We used Western blot analysis to measure MMP-12 levels in
BALF samples from NHPs exposed to air (nZ 3) or CS for 4
weeks (n Z 3) and 12 weeks (n Z 3), and in radio-
immunoprecipitation assay extracts of BAL leukocytes from743
Polverino et alNHPs exposed to air (nZ 7) or CS for 4 weeks (nZ 4) or
12 weeks (n Z 7). Brieﬂy, equal amounts of total protein
(30 mg) were reduced by adding Laemmli sample buffer
containing dithiothreitol and heating to 90C for 5 minutes.
Proteins in the samples were separated on 12% SDS-
polyacrylamide gels for 4 hours at 90 V. Proteins were
then transferred to polyvinylidene diﬂuoride membranes,
blocked in phosphate-buffered saline (PBS) containing 3%
nonfat milk and 0.1% Tween-20 for 2 hours at room tem-
perature, and incubated overnight with rabbit antieMMP-
12 IgG (diluted 1:100; Abcam, Cambridge, MA) and rabbit
anti-vinculin IgG (diluted 1:1000; Abcam) as a loading
control. After washing the membranes with PBS contain-
ing 0.1% Tween-20, the membranes were incubated
with horseradish peroxidaseeconjugated goat anti-rabbit
IgG (diluted 1:3000; BioRad, Hercules, CA) for 2 hours
at room temperature, and developed using a chem-
iluminescence substrate (Thermo Scientiﬁc, Pittsburgh,
PA) following the manufacturer’s directions. The mem-
branes were exposed to a charge-coupled device camera for
30 minutes (BioRad). Signals were quantiﬁed using
densitometry with Scion Image software for Windows Beta
4.0.2 (Scion Corporation, Bethesda, MD), and MMP-12
signals were corrected for vinculin signals.
Pulmonary Inﬂammation Measured in Lung Sections
To identify the inﬂammatory cell subsets that were recruited
into the lung parenchyma of CS-exposed NHPs, we per-
formed immunoﬂuorescence staining for markers of macro-
phages and polymorphonuclear neutrophils in formalin-ﬁxed
lung sections from NHPs exposed to air or CS for 12 weeks
(n Z 5 per group). Brieﬂy, the lung sections were depar-
afﬁnized, and antigen (Ag) retrieval was performed by
heating the slides in a microwave in 0.01 mol/L sodium cit-
rate and 2 mmol/L citrate buffer (pH 6.0). The sections were
incubated for 1 hour at 37C with either a murine IgG to
human myeloperoxidase (diluted 1:20) as a marker of neu-
trophils or a rabbit anti-human CD68 IgG (diluted 1:20) as a
marker of macrophages. Isotype-matched nonimmune mu-
rine and rabbit IgGs were used as controls. After washing the
lung sections with PBS, the sections were incubated at 37C
for 1 hour with Alexa 488econjugated goat anti-murine
F(ab’)2 diluted 1:100 or Alexa 488econjugated goat anti-
rabbit F(ab’)2 diluted 1:100. Sections were then washed in
PBS, and nuclei were counterstained with DAPI. Images of
the stained lung sections were analyzed using a confocal
microscope (Leica Microsystems, Buffalo Grove, IL).
Confocal micrographs were recorded under a ﬂuorescence
imaging mode in which cells were exposed to 488-nm light
attenuated by an acustotunable optical ﬁlter.29
Lymphoid Aggregates
To quantify the number of lymphoid aggregates present in the
airways and lung parenchyma, parafﬁn-embedded sections744(5 mm thick) of lungs from NHPs exposed to air or CS for 12
weeks (seven animals per group) were stained with hema-
toxylin and eosin. For each NHP, 30 high-magniﬁcation ﬁelds
were counted in a randomized manner using a Leica epi-
ﬂuorescence microscope (Leica Microsystems). We evaluated
all lymphoid aggregates containing >40 contiguous mono-
nuclear cells. Data were expressed as the number of paren-
chymal, peribronchial, and perivascular lymphoid aggregates/
mm2 of tissue examined in 30 randomly acquired images
per animal.
To identify B- and T-lymphocyte subsets within the
lymphoid aggregates,we performed triple-immunoﬂuorescence
staining of lung sections from NHPs exposed to air or CS for
12 weeks (nZ 5 lung sections per group). Brieﬂy, the lung
sections were deparafﬁnized, and Ag retrieval was per-
formed by heating the slides in a microwave in 0.01 mol/L
sodium citrate and 2 mmol/L citrate buffer (pH 6.0). The
sections were incubated for 2 hours at 37C with murine anti-
human CD4 IgG (diluted 1:50; Abcam), then for 1 hour at
37C with rat anti-human CD8 IgG (diluted 1:100; Abcam),
and then overnight at 4C with rabbit anti-human CD20 IgG
(diluted 1:100; Abcam). After washing the lung sections with
PBS, the sections were incubated at 37C for 1 hour with
Alexa Cy5-conjugated goat anti-murine IgG (diluted 1:100),
Alexa 546econjugated goat anti-rat IgG (diluted 1:100), and
Alexa 488econjugated F(ab’)2 fragment of goat anti-rabbit
IgG (diluted 1:100). Sections were then washed in PBS, and
nuclei were counterstained with DAPI. Images of the stained
lung sections were analyzed using a confocal microscope
(Leica Microsystems). Confocal micrographs were recorded
under ﬂuorescence imaging mode in which cells were exposed
to 488-, 570-, and 670-nm light attenuated by an acustotunable
optical ﬁlter.29
Mucus Metaplasia
Lung sections from seven NHPs exposed to air and eight
NHPs exposed to CS for 4 or 12 weeks were stained with
periodic acideSchiff stain using commercial kits (Sigma-
Aldrich, St. Louis, MO) following the manufacturer’s
instructions. We also immunostained lung sections from
NHPs that were exposed to air (nZ 6) or CS (nZ 10) for
4 or 12 weeks for MUC5AC. Brieﬂy, the lung sections
were deparafﬁnized, and Ag retrieval was performed by
heating the slides in a microwave in 0.01 mol/L sodium
citrate and 2 mmol/L citric acid buffer citrate buffer (pH
6.0). Sections were incubated with blocking medium (PBS
containing 1% normal donkey serum, 3% bovine serum
albumin, 1% gelatin, 0.2% Triton X-100, and 0.2%
saponin) at 37C for 30 minutes and then washed in 1%
bovine serum albumin, followed by 0.05% Brij-35, and
then incubated overnight at 4C with murine anti-human
MUC5AC IgG1 (diluted 1:500; Chemicon, Billerica,
MA) or nonimmune murine IgG to identify cells under-
going mucus metaplasia within the bronchial epithelium.
After washing in PBS containing 1% bovine serumajp.amjpathol.org - The American Journal of Pathology
Figure 1 Cigarette smoke (CS) exposure
increases bronchoalveolar lavage (BAL) leukocyte
counts in nonhuman primates (NHPs). NHPs were
exposed to air (n Z 8; white bars) or CS (n Z 8;
gray bars) for 12 weeks, and BAL was performed at
baseline and after 4 and 12 weeks of air or CS
exposure. Total and differential leukocyte counts
were performed on BAL samples (top and middle
panels, F). A: BAL total leukocyte counts. B: BAL
macrophage counts. C: BAL polymorphonuclear
neutrophil (PMN) counts. D: BAL lymphocyte
counts. E: Lung sections stained for hematoxylin
and eosin from NHPs exposed to air or CS for 12
weeks. The black arrow indicates an inﬂammatory
cell inﬁltrate in the bronchial lumen; blue arrows,
inﬂammatory cells inﬁltrating the airway walls.
Images shown in E and F are representative of ﬁve
animals per group. F: Lung sections from NHPs
exposed to CS or air for 12 weeks. Lung sections
were immunostained with Alexa 488 and a PMN
marker [myeloperoxidase (MPO)] or a macrophage
marker (CD68). Bottom panels: Lung sections from
CS-exposed NHPs immunostained with isotype-
matched murine and rabbit control primary IgG
antibodies. Data are expressed as means  SEM
(AeD). *P < 0.05, **P < 0.01, and ***P  0.001
versus the group indicated and the same group at
baseline (AeD). Original magniﬁcations: 300
(MPO staining; F); 500 (CD68 staining; F). WBC,
white blood cell.
Smoke-Induced Airway Disease in NHPsalbumin followed by 0.05% Brij, the sections were
incubated at 37C for 1 hour with Alexa 556econjugated
donkey anti-murine IgG diluted 1:300. Sections were then
washed in PBS, and nuclei were counterstained with DAPI.
Immunoﬂuorescence was imaged using Axioplan 2 (Carl
Zeiss, Inc., Thornwood, NY) with a Plan-Neoﬂuor 40/0.75
air objective and a charge-coupled device camera (Hama-
matsu Photonics, Hamamatsu, Japan) with the acquisition
software Slidebook 5.0 version 5.0.0.1 (Intelligent Imaging
Innovation, Denver, CO).
Submucosal Gland Hyperplasia and Hypertrophy
Lung sections from NHPs exposed to air (nZ 8) and CS for 4
(nZ4) and12 (nZ8)weekswereperiodic acideSchiff stained
(as outlined above), and themean number of submucosal glands
was counted in all large cartilaginous bronchi in the tissue sec-
tions from each animal. Themean size of the submucosal glandsThe American Journal of Pathology - ajp.amjpathol.orgwas also quantiﬁed using MetaMorph software version 7.7.0.0
(Molecular Devices, Wetzlar, Germany).
Airway and Vessel Remodeling
Extracellular matrix (ECM) protein deposition around small
airways and vessels was assessed in parafﬁn-embedded and
formalin-ﬁxed lung sections from NHPs exposed to air or CS
for 12 weeks (nZ 5 per group), stained with Masson’s tri-
chrome stain using a commercial kit (Sigma-Aldrich). Large
airways were deﬁned as airways having cartilage, whereas
small airways were deﬁned by those lacking cartilage.
MetaMorph software was used to quantify the mean thick-
ness of the layer of proteins stained blue by Masson’s tri-
chrome stain. The area of ECM protein deposited around
vessels and airways was quantiﬁed in pixels2 per unit internal
circumference of the vessel and per length of the bronchial
wall in pixels.745
Figure 2 Cigarette smoke (CS) exposure increases inﬂammatory cyto-
kine and matrix metalloproteinase 9 (MMP-9) levels (but not MMP-12
levels) in nonhuman primate (NHP) bronchoalveolar lavage ﬂuid (BALF)
samples, and modestly increases levels of MMP-12 in BAL leukocytes.
Levels of chemokine ligand (CCL) 2 (A), CXCL8 (B), IL-6 (C), and MMP-9
(D) in BALF samples from NHPs exposed to air or CS for 12 weeks. C:
There is a trend toward an increase in BALF IL-6 levels in CS-exposed NHPs
(P Z 0.1). E: Equal amounts of total protein in BAL leukocyte extracts
were subjected to Western blot analysis for MMP-12, and vinculin was used
as a loading control. F: Quantiﬁcation of proeMMP-12 in BAL leukocyte
extracts by Western blot analysis. The proeMMP-12 signals were normal-
ized to signals for a housekeeping protein (vinculin) and expressed as fold
change relative to corrected signals in cells from the air-exposed NHPs.
Data are for BAL leukocytes isolated from seven NHPs exposed to air, four
in NHPs exposed to CS for 4 weeks, and seven NHPs exposed to CS for 12
weeks. Data are presented as means  SEM (AeD and F). nZ 8 NHPs per
group (AeD). *P < 0.05 compared with signals in cells from air-exposed
NHPs (AeD and F).
Polverino et alAirspace Measurement
Lungs of NHPs exposed to air or CS for 12 weeks (eight
animals per group) were inﬂated to 25 cm H2O pressure,
removed, ﬁxed in 10% buffered formalin, and parafﬁn
embedded. Lung sections from all of the lobes were cut (5 mm
thick), deparafﬁnized, and stained with hematoxylin and
eosin. Digital images of the stained slides were captured
using an Olympus NanoZoomer (Hamamatsu Photonics)
slide scanner with a 20 objective, and the VisioMorphDP
module of VisioPharm analysis software (VisioPharm,
Horsholm, Denmark) was used to measure alveolar volume.
Volume-weighted mean volumes of alveoli were measured
using the method of point-sampled intercepts.30 This method
combines measurements of both mean volume and variability
of size of the speciﬁed parenchymal airspaces. The volume-
weighted mean volumes of alveoli can be estimated on a
single section, and the estimation is unbiased without shape
assumptions.31,32
Oxidative Stress
Thiobarbituric acidereactive substances (a measure of lipid
peroxidation) were measured in homogenates of lung tissue
using a commercial kit (Cayman Chemical Company, Ann
Arbor, MI) following the manufacturer’s instructions. In
addition, we performed immunoﬂuorescence staining of
peripheral lung sections from NHPs exposed to air or CS for
12 weeks (n Z 4 per group) with rabbit IgG to human
4-hydroxynonenal (4-HNE; Bioss, Woburn, MA) incubated
at 37C for 1 hour at a 1:50 dilution or nonimmune rabbit
IgG as a control. After washing the lung sections with PBS,
the sections were incubated at 37C for 1 hour with Alexa
488econjugated goat anti-rabbit F(ab’)2, diluted 1:100.
Sections were then washed in PBS, and nuclei were coun-
terstained with DAPI. Images of the stained lung sections
were analyzed using an epiﬂuorescence microscope, as
described above.
Alveolar Septal Cell Apoptosis
Alveolar septal cell apoptosis was measured in lung sections
from NHPs exposed to air (n Z 4) or CS (n Z 5) for 12
weeks using terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) staining with
an Apoalert DNA Fragmentation Detection Kit (Clontech
Laboratories, Mountain View, CA) following the manu-
facturer’s instructions, using TdT terminal transferasee
negative TUNEL as control. In addition, we stained lung
sections for active (cleaved) caspase-3. Lungs were depar-
afﬁnized, and Ag retrieval was performed by heating the
slides in a microwave in citrate buffer (see above). The
sections were incubated for 1 hour at 37C with a murine
IgG to human active caspase-3 (diluted 1:100; Abcam) or
nonimmune murine IgG as control. After washing the lung
sections with PBS, the sections were incubated at 37C for7461 hour with Alexa 488econjugated goat anti-rabbit F(ab’)2,
diluted 1:100. Sections were then washed in PBS, and
nuclei were counterstained with DAPI. MetaMorph soft-
ware was used to quantify apoptotic cells for both assays.
The number of apoptotic cells was normalized by unit of
alveolar wall area.
Statistical Analysis
Data are presented as means  SD for continuous vari-
ables. Parametric data were analyzed using the Student’s
t-test, whereas the U-test was used for nonparametric data.
P < 0.05 was considered to be statistically signiﬁcant.
Analyses were completed using SigmaStat version 2.03
(Systat Software, San Jose, CA) and GraphPad Prism 6
(GraphPad Software Inc., San Diego, CA).ajp.amjpathol.org - The American Journal of Pathology
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CS Induces Pulmonary Inﬂammation Detected in BAL
Samples in NHPs
We performed an initial experiment to determine whether
exposing NHPs to CS versus air for up to 4 weeks results in
signiﬁcant pulmonary inﬂammation and airway pathologies,
including mucus metaplasia, because these events can be
detected soon after humans start smoking and long before they
develop COPD.33 In the second experiment, we exposed
NHPs to CS or air up to 12 weeks to determine whether longer
CS exposures increase pulmonary inﬂammation and mucus
metaplasia further, and to assess whether NHPs exposed to CS
for 12 weeks also develop other airway pathologies (small
airway remodeling), airspace disease (emphysema), signs of
adaptive immune responses (lymphoid aggregates), abnor-
malities in lung physiology (airﬂow obstruction and increases
in lung compliance), and measures of systemic inﬂammation
characteristic of human COPD.
Exposing NHPs to CS (n Z 8) resulted in signiﬁcant
increases in total leukocyte counts in BAL samples compared
with air-exposed NHPs (nZ 8) detected as early as 1 week of
CS exposure (means  SEM: 1.7  0.1  106 versus
1.1 0.13 106 leukocytes, respectively; P< 0.005). Total
leukocyte counts increased after 4 weeks and remained
elevated after 12 weeks of CS exposure (Figure 1A). The
increases in BAL leukocyte counts were due mainly to
increases in macrophage counts (Figure 1B). On average,
macrophages represented 92% and 70.8% of the BAL leu-
kocytes at baseline and after 12 weeks of CS exposure,
respectively. Signiﬁcant increases in BAL macrophage
counts were detected as early as 1 week of CS exposure
(means  SEM: 1.4  0.1  106 versus 1.0  0.1  106
macrophages for CS- versus air-exposed NHPs, respectively;
P< 0.05) in the 4-week exposure study. Signiﬁcant increases
in BAL PMN counts were detected after 4 weeks of CS
exposure (Figure 1C). On average, PMNs represented 0.76%
and 2.9% of BAL leukocytes at baseline and after 4 weeks of
CS exposure, respectively. BAL PMN counts remained
elevated after 12 weeks of CS exposure. In contrast,
lymphocyte counts did not signiﬁcantly increase until NHPsFigure 3 Cigarette smoke (CS) exposure increases lymphoid aggregate
counts in nonhuman primate (NHP) lungs. A: Hematoxylin and eosin staining
of lung sections from NHPs exposed to air or CS for 12 weeks. Top, middle,
and bottom panels: Lymphoid aggregates in or around lung parenchyma,
vessels, and bronchi, respectively, are indicated by arrows. BeD: Quanti-
tation of lymphoid aggregates in parenchyma (B), and around vessels (C)
and bronchi (D) in the lungs of air- and CS-exposed NHPs normalized to the
area of the tissue in each microscopic ﬁeld (30 randomly captured ﬁelds per
animal). E: Triple-color immunoﬂuorescence staining of a lymphoid aggre-
gate in a representative lung section from a CS-exposed NHP. B lymphocytes
are identiﬁed with a green ﬂuorophore; CD8þ T lymphocytes, a red ﬂuo-
rophore; and CD4þ T lymphocytes, a yellow ﬂuorophore. Data are presented
as means SEM (BeD). nZ 7 NHPs per group (BeD). *P < 0.05 versus the
air-exposed NHPs (BeD). Original magniﬁcation, 400 (A and E).
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Figure 4 Cigarette smoke (CS) induces mucus metaplasia in large and
small airways. Lung sections from nonhuman primates (NHPs) exposed to
air or CS for 12 weeks stained with periodic acideSchiff stain (A) or
immunostained with a red ﬂuorophore for MUC5AC (B). Nuclei were
counterstained with DAPI. C and D: The number of cells undergoing mucus
metaplasia in the large (C) and small (D) airways of NHPs exposed to air
(nZ 7) or CS (nZ 8) for 12 weeks. E: Representative images of the airway
submucosal glands in air- and CS-exposed NHPs. The blue arrow indicates a
larger submucosal gland in the airway of the CS-exposed NHP when
compared with the single submucosal gland in the air-exposed NHP; and
black arrows, hyperplasia of submucosal glands in the CS-exposed NHP. C
indicates cartilage present in the large airways. F and G: The quantitative
assessment of the number of submucosal glands per airway and the mean
size of submucosal glands in the airways of NHPs exposed to CS (nZ 8) or
air (nZ 8) for 12 weeks. Data are means  SEM (C, D, F, and G). *P < 0.05
compared with air-exposed NHPs (C, D, F, and G).
Polverino et alhad been exposed to CS for 12 weeks (Figure 1D). On
average, lymphocytes represented 2.7% and 6.6% of all BAL
leukocytes at baseline and after 12 weeks of CS exposure,
respectively.
CS Induces the Accumulation of Leukocytes in the
Airway Walls and Lumen and the Peripheral Lungs of
NHPs
Examination of hematoxylin and eosinestained lung sec-
tions from NHPs exposed to air or CS for 12 weeks revealed
inﬁltration of the airway walls with inﬂammatory cells along
with inﬂammatory cells in the lumen of the CS-exposed
NHPs but no airway inﬂammation in the lungs of air-
exposed NHPs (Figure 1E). When we immunostained lung
sections with markers of leukocyte subsets, we observed
increased numbers of PMNs (myeloperoxidase-positive
cells) and macrophages (CD68-positive cells) in the distal
lung parenchyma (Figure 1F) as well as in the airway walls
(data not shown) of NHPs exposed to CS when compared to
air-exposed animals. There was no staining in lung sections
stained with isotype-matched nonimmune control antibodies
for either the PMN marker or the macrophage marker.
CS Increases BALF Levels of Proinﬂammatory Mediators
and MMP-9
Levels of CCL2, CXCL8, and IL-6 were measured in BALF
samples from NHPs exposed to air and CS for 12 weeks.
These cytokines were selected on the basis of their known
potent activities in stimulating the recruitment (and/or acti-
vation) of monocytes (CCL2 and IL-6) and PMNs (CXCL8
and IL-6) into the CS-exposed lung.34,35 BALF levels of
CCL2 and CXCL8 were signiﬁcantly increased after 12
weeks of CS exposure (Figure 2, A and B), and there was a
strong trend (P Z 0.1) toward higher BALF levels of IL-6
in CS-exposed NHPs (Figure 2C).
We also compared lung levels of MMP-9 and MMP-12 in
BAL samples from air-versus CS-exposed NHPs because
MMP-9 is the major MMP released by CS-activated human
lung macrophages, whereas MMP-12 is the major MMP
released by CS-activated lung macrophages from commonly
studied small experimental animals, including mice and
guinea pigs.36 MMP-9 levels were robustly (approximately
sixfold) increased in BALF samples after 12 weeks of CS
exposure (Figure 2D). In contrast, we did not detect any
MMP-12 signals in BALF samples from NHPs exposed to
either air or CS for up to 12 weeks using Western blot
analysis (data not shown). However, we detected MMP-12 in
extracts of BAL leukocytes from NHPs (Figure 2E). The
main form detected was proeMMP-12, and only weak sig-
nals corresponding to active MMP-12 were detected in these
samples. ProeMMP-12 levels in BAL leukocytes were
increased 2.7-fold after 4 weeks of CS exposure and twofold
after 12 weeks of CS exposure when compared with levels in
BAL leukocyte air-exposed animals (Figure 2F). Active748MMP-12 levels in BAL leukocytes from NHPs exposed to
CS for 12 weeks were modestly, but signiﬁcantly, increased
(144.5  SD 25.3% of levels in cells from air-exposed ani-
mals; PZ 0.013; nZ 4 NHPs per group) when corrected for
vinculin signals (used as a loading control).ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Cigarette smoke (CS) induces extracellular matrix (ECM) protein
deposition around small airways and vessels in nonhuman primate (NHP) lungs.
A and B: Lung sections from NHPs exposed to air or CS for 12 weeks immuno-
stained with Masson’s trichrome stain to visualize deposition of ECM proteins
(visualized as blue staining) around small airways (A) and vessels (B) of NHPs
exposed to CS for 12 weeks compared with NHPs exposed to air. C and D:
Quantitation of ECM protein deposition around bronchi and small vessels,
respectively, in air- and CS-exposed animals normalized to the length of the
bronchial wall or the length of the vessel internal circumference, respectively.
Data are means þ SEM (C and D). nZ 5 NHPs per group (C and D). *P< 0.05
versus air-exposed animals (C and D). Original magniﬁcation,200 (A and B).
Smoke-Induced Airway Disease in NHPsCS Increases Lymphoid Aggregate Numbers in NHP
Lungs
In addition to increases in numbers of innate immune cell
counts in the lungs, human COPD patients develop an
adaptive immune response characterized by the formation of
lymphoid follicles and aggregates around the airways and in
the lung parenchyma.37,38 NHPs exposed to CS for 12 weeks
developed increased numbers of lymphoid aggregates in their
lung parenchyma (Figure 3, A and B) and around pulmonary
vessels (Figure 3, A and C) and airways (Figure 3, A and D).
The lymphoid aggregates were mainly composed of CD20þ
B cells and CD4þ T lymphocytes in their centers and CD8þ T
lymphocytes in their peripheries (Figure 3E), as reported for
lymphoid aggregates/follicles in human COPD lungs.38
CS Exposure Induces Mucus Metaplasia in the Large
and Small Airways of NHPs
NHP lung sections stained with periodic acideSchiff stain
(Figure 4A) or immunostained for MUC5AC (Figure 4B)
revealed that air-exposed NHPs had few airway mucin-
expressing cells, but mucus cell metaplasia was readily
evident in airway epithelia of NHPs exposed to CS for 4
weeks and increased further after 12 weeks of CS exposure.
Mucus cell metaplasia was present in the epithelia of both
large (cartilaginous) and small (noncartilaginous) bronchi in
the CS-exposed animals (Figure 4, C and D, respectively). In
addition, NHPs exposed to CS for 12 weeks had increases in
submucosal glands in their large airways (Figure 4E),
including submucosal gland hyperplasia (Figure 4F) and
submucosal gland hypertrophy (Figure 4G).
CS Exposure Induces Small Airway and Vessel
Remodeling in NHPs
Masson’s trichrome staining of lung sections revealed
increased deposition of ECM proteins around small (non-
cartilaginous) bronchi (Figure 5, A and C) and small vessels
(Figure 5, B and D) in the lungs of NHPs exposed to CS for
12 weeks. The deposition of ECM proteins around airways
and vessels was also present (albeit not as severe) in the
lung of NHPs exposed to CS for 4 weeks (data not shown).
CS Does Not Cause Airspace Enlargement in NHPs
In addition to airway disease, airspace enlargement is a
common pathology in human COPD lungs and contributes
to the airﬂow obstruction that is characteristic of human
COPD.39 However, NHPs did not develop signiﬁcant
airspace enlargement after 12 weeks of CS exposure
(means  SEM alveolar space area for CS-exposed NHPs:
4.90  106  0.53  106 mm2 versus 4.39  106  0.43 
106 mm2 for air-expose NHPs). Nevertheless, distal lung
pathologies that contribute to emphysema development,
including pulmonary inﬂammation (vide supra) andThe American Journal of Pathology - ajp.amjpathol.orgoxidative stress and alveolar septal cell apoptosis (vide
infra), were affected by 12 weeks of CS exposure.7
CS Increases Oxidative Stress in NHP Lungs
NHPs exposed to CS for 12weeks had increased lung levels of
thiobarbituric acidereactive substances (a measure of lipid
peroxidation)40 (Figure 6A) when compared with NHPs
exposed to air for 12 weeks. To identify the cells that produce
reactive oxygen species or reactive nitrogen species in the
CS-exposed NHP lung, we immunostained lung sections with
an antibody to 4-hydroxy-nonenal (4-HNE), which is a major
aldehyde product ofu-6-unsaturated fatty acid peroxidation.41
Robust 4-HNE staining was detected in the lungs of
CS-exposed animals mainly in inﬂammatory cells (Figure 6B)
and lymphoid aggregates (Figure 6C), whereas the lungs of
air-exposed NHPs showed minimal 4-HNE staining
(Figure 6D). Lung sections stained with isotype-matched
nonimmune control antibodies showed no staining (Figure 6E).
CS Increases Alveolar Septal Cell Apoptosis in NHPs
The number of TUNEL-positive (Figure 7, A and B) and
active (cleaved) caspase 3epositive (Figure 7, C and D)749
Figure 6 Cigarette smoke (CS) increases oxidative stress levels in
nonhuman primate (NHP) lungs. NHPs were exposed to air or CS for up to
12 weeks. A: Thiobarbituric acidereactive substances (TBARS, expressed as
micromoles of TBARS per nanogram of protein) were measured in whole
lung samples from air- and CS-exposed animals. BeD: A representative lung
section immunostained for 4-hydroxynonenal (4-HNE) from NHPs exposed
to CS (B and C) or air (D) for 12 weeks and the corresponding bright-ﬁeld
images. Intense staining for 4-HNE is detected in lung inﬂammatory cells
(B) and lymphoid aggregates (C) in the lung of CS-exposed NHPs identiﬁed
in the bright-ﬁeld images. Staining for 4-HNE is detected in only a few
resident lung macrophages in air-exposed NHPs. D: Green arrow indicates a
4-HNEestained macrophage; and white arrows, 4-HNEenegative macro-
phages. Images shown are representative of those from four NHPs per
group. E: An image of a lung section stained with a rabbit non-immune
control primary antibody. Data are presented as means  SEM (A). n Z 8
air-exposed animals and n Z 7 CS-exposed animals per group (A).
**P < 0.01 versus the air-exposed NHPs (A). BeE: Nuclei were counter-
stained with DAPI. Original magniﬁcation, 200 (BeE). Rb, rabbit.
Polverino et alcells was signiﬁcantly increased in the alveolar septae of
NHPs exposed to CS for 12 weeks when compared with that
in air-exposed animals. Few apoptotic cells were detected
after 4 weeks of CS exposure (data not shown).
PFTs in CS-Exposed NHPs
Exposure of NHPs to CS caused no statistically signiﬁcant
effects on PFT results during the 12-week study period. CS
exposure did not affect quasistatic compliance, forced vital
capacity, or individual measures of forced expiratory ﬂows
(Table 2) (data not shown). The forced expiratory volume in
0.1 seconds was similar in the air- and CS-exposed groups at
baseline and at the 4-week time point. However, after 12
weeks of CS exposure, there was a strong trend toward lower
forced expiratory volume in 0.1 seconds in the CS- versus air-
exposed NHPs (PZ 0.088) (Table 2). Also, NHPs exposed to
air for 12 weeks had a small decrease in mean chord compli-
ance (7.6% reduction), whereas NHPs exposed to CS had a
20% increase in mean chord compliance (data not shown).
CS Does Not Induce Loss of Body Weight or a Systemic
Inﬂammatory Response in NHPs
NHPs exposed to CS did not have signiﬁcant loss of body
weight over the 12-week exposure period (data not shown).
We also did not detect signiﬁcant changes in serum levels of
IL-6, CCL2, CXCL8, or MMP-9 in NHPs after 4 or 12
weeks of CS exposure when compared with air-exposed
NHPs (data not shown).
Discussion
We show, for the ﬁrst time, that CS-exposed NHPs develop
changes in their airways that are similar to those occurring in
human COPD patients, including the following: i) airway
inﬂammation, ii) large and small airway mucus metaplasia,
iii) airway submucosal gland hypertrophy and hyperplasia,
iv) the development of lymphoid aggregates around the air-
ways, and v) small airway ﬁbrosis. Thus, CS-exposed NHPs
develop more robust airway pathologies than CS-exposed
mice for 12 weeks. Unlike CS-exposed small animals, our
study shows that CS-exposed NHPs can safely undergo
longitudinal BAL sampling. Thus, CS-exposed NHPs can
serve as a useful large animal model of human COPD airway
pathologies. CS-exposed NHPs may also be useful for serial
sampling for COPD biomarker studies and studies of thera-
peutics targeting mucus hypersecretion and/or small airway
remodeling.
Small Airway and Vessel Remodeling
Small airway remodeling is an important cause of airﬂow
obstruction in COPD patients.37,42 We now report that
exposing NHPs to CS produces robust deposition of ECM
proteins around small airways. It is likely that these airway750 ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Cigarette smoke (CS) exposure induces alveolar septal cell apoptosis in peripheral lung. Nonhuman primates (NHPs) were exposed to air or CS
for 12 weeks, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was performed on formalin-ﬁxed lung sec-
tions. A: Quantiﬁcation of TUNEL-positive cells in air- and CS-exposed groups normalized to unit area of the alveolar wall. B, top panels: Representative
images of TUNEL staining of lung sections from air- and CS-exposed NHPs. Arrows indicate TUNEL-positive cells. B, bottom panel: Lung sections from
CS-exposed NHPs that were subjected to TUNEL staining with the terminal deoxynucleotidyl transferase (TdT) enzyme omitted as a negative control.
C: Quantiﬁcation of active caspase-3epositive alveolar septal cells in air- and CS-exposed NHP lungs normalized to area of lung tissue. D, top panels:
Representative images of active caspase-3 staining in the lungs of air- and CS-exposed NHPs. Arrows indicate active caspase-3epositive cells. D, bottom
panel: Lung sections from CS-exposed NHPs immunostained with isotype-matched murine (Ms) control primary IgG antibody. Data are presented as
means  SEM (A and C). nZ 4 air-exposed NHPs and nZ 5 CS-exposed NHPs per group (A); nZ 5 NHPs per group (C). *P< 0.05 versus air-exposed NHPs
(A and C). Original magniﬁcation, 600 (D).
Smoke-Induced Airway Disease in NHPschanges contributed to the trend toward the reductions in
forced expiratory volume in 0.1 seconds (a readout of
airﬂow obstruction) observed in CS-exposed NHPs. Mice
require 24 weeks of CS exposure before they develop
relatively mild airway ﬁbrosis,43 whereas NHPs develop
robust small airway remodeling after only 12 weeks of CS
exposure. The extent of the small airway ECM protein
deposition is greater in CS-exposed NHPs than mice
(3 versus 1.5-fold increases, respectively43,44). Prior studies
have reported thickened basement membranes and smooth
muscle hypertrophy in allergen-exposed NHPs,45e47 and
chronic respiratory bronchiolitis associated with restricted
airﬂow in ozone-exposed NHPs.48 Interestingly, we also
detected ﬁbrosis around the small vessels in CS-exposed
NHPs, which has not been reported previously in NHP
models of airway disease.
Mucus Metaplasia
Mucus hypersecretion due to mucus metaplasia and submu-
cosal gland hypertrophy and hyperplasia19 occurs in COPD
patients, and predisposes patients to the development of acute
exacerbations.49 A major limitation of CS-exposed mice as a
COPD model system is that mice lack submucosal glands,
have few goblet cells, and only develop mild airway mucusThe American Journal of Pathology - ajp.amjpathol.orgcell metaplasia after 24 weeks of CS exposure.3 However,
CS-exposed NHPs developed impressive hyperplasia and
some hypertrophy of bronchial submucosal glands, and
extensive mucus metaplasia both in their large cartilaginous
and noncartilaginous airways within 4 weeks of CS exposure.
These results suggest that CS-exposed NHPs are a useful
model system for testing novel therapeutics for mucus
hypersecretion.
Lung Inﬂammation
NHPs exposed to CS had increases in lungmyeloid leukocyte
counts similar to those seen in COPD patients. Macrophages
(an important culprit in human COPD50) were the main
leukocyte subset increased in the CS-exposed NHP lungs, as
reported for other CS-exposed animals, including mice.
PMNs also play a key role in the pathogenesis of human
COPD by promoting destruction of the alveolar walls during
emphysema development via their complement of serine
proteinases and MMPs.51 Although PMNs represent only a
small percentage of the BAL leukocytes in CS-exposed
mice,52 lung PMN counts increased approximately 12-fold
in CS-exposed NHPs. We also detected increases in BALF
levels of mediators that recruit and activate these myeloid
leukocytes in the lung (CCL2, CXCL8, and IL-6). Lung751
Table 2 Lung Function of NHPs in Response to CS Exposure
Lung function Air CS
FEV0.1 (mL)
Baseline 50 (5.6) 50 (10.4)
4 Weeks 46 (12) 45 (9.4)
12 Weeks 43 (12.5) 33 (9)*
Cst (mL/cm H2O)
Baseline 13 (3.5) 10 (5)
4 Weeks 11.6 (3) 11.5 (5.2)
12 Weeks 12 (2.4) 12 (5)
Pulmonary function testing using whole-body plethysmography was
performed on NHPs at baseline and after 4 and 12 weeks of air or CS
exposure. Data are presented as means  SEM. n Z 8 NHPs per group.
*Trend toward lower FEV0.1 in NHPs exposed to CS for 12 weeks compared
with NHPs exposed to air for 12 weeks (P Z 0.088).
CS, cigarette smoke; Cst, quasistatic compliance calculated from the lung
volume-pressure ﬂow curves; FEV0.1, forced expiratory volume in 0.1 sec-
onds; NHP, nonhuman primate.
Polverino et alinﬂammatory responses to injury in NHPs have not been well
studied previously. However, NHPs infected with Bacillus
anthracis develop robust systemic and pulmonary inﬂam-
mation, and lung injury associated with high mortality.53
We found impressive increases in MMP-9 levels in
BALF samples, which were likely derived from activated
macrophages (as well as epithelial cells and PMNs in the
lung54e56). However, we did not detect MMP-12 in BALF
samples in any animal tested, even after 12 weeks of CS
exposure, and MMP-12 levels increased only modestly in
BAL leukocyte extracts from CS-exposed NHPs. Activated
macrophages from humans and mice differ in the proﬁles of
MMPs that they produce, with MMP-9 being the main
MMP produced by human cells, whereas MMP-12 is the
major MMP produced by murine macrophages.36 Thus,
from the expression proﬁle of MMPs that we detected in
BALF samples, CS-exposed NHPs more closely resemble
human COPD patients than CS-exposed mice.Adaptive Immunity
CS-exposed NHPs also had evidence of activation of adap-
tive immune responses, with increases in BAL lymphocyte
counts and lymphoid aggregates in the airways and lung
parenchyma that were mainly composed of mature B lym-
phocytes and CD4þ and CD8þ T lymphocytes. Increased
numbers of lymphoid follicles or aggregates are present in
both the small airways and the peripheral lungs of patients
with severe COPD37 and CS-exposed mice,57 and lymphoid
follicles have been strongly implicated in the pathogenesis of
COPD.57 In CS-exposed mice, the number of aggregates is
signiﬁcantly higher after 6 months than 2 or 4 months of CS
exposure.58 However, NHPs developed eightfold increases
in lung lymphoid aggregate counts after only 12 weeks of CS
exposure. The antigenic stimuli that trigger the formation of
B-cell follicles in COPD patients include microbial Ags,58
Ags in CS,38,59 proteolytic fragments of ECM proteins,60752and epithelial neo-Ags.61 However, the antigenic stimuli
that caused the development of lymphoid aggregates in CS-
exposed NHPs were not identiﬁed in our study. Whether
the activated B cells and CD4þ T cells in these follicles
collaborate to generate autoantibodies that amplify lung
inﬂammation and destruction in NHPs, as occurs in COPD
patients,60,62e64 will be the focus of future studies.
Airspace Size
We did not observe airspace enlargement in the CS-exposed
NHPs. Likely, signiﬁcantly >12 weeks of CS exposure is
required for NHPs to develop emphysema. It was not
possible for us to expose NHPs to CS for periods >12
weeks because of the prohibitively high costs associated
with these CS exposure durations. However, CS-exposed
NHPs developed increases in three key lung processes that
lead to the development of emphysema: pulmonary
inﬂammation (vide supra) and lung oxidative stress levels
and rates of alveolar septal cell apoptosis (vide infra).
Oxidative Stress
NHPs exposed to CS had robust increases in lung oxidative
stress levels localized mainly to leukocytes in the paren-
chyma and lymphoid aggregates. CS contains oxidizing
toxicants and, when inhaled, induces the release of reactive
oxygen species and reactive nitrosylated species by acti-
vated PMNs, macrophages, and epithelial cells in the
lungs.7,65 Reactive oxygen species and reactive nitrogen
species can injure lung ECM proteins either directly or
indirectly by activating latent MMPs and/or inactivating
proteinase inhibitors to thereby promote proteolytic
destruction of the alveolar walls.7,39,66
Alveolar Septal Cell Apoptosis
This process also contributes to the loss of alveolar walls in
COPD patients.67 In mice and rats treated with vascular
endothelial growth factor receptor antagonists, apoptosis of
alveolar endothelial or epithelial cells is sufﬁcient to cause
pulmonary emphysema in the absence of lung inﬂamma-
tion.67,68 Alveolar septal cell apoptosis was detected in
CS-exposed NHPs likely in both type I and type II alveolar
epithelial cells on the basis of analysis of bright-ﬁeld images
of the lung sections. CS itself and CS-induced lung inﬂam-
mation may have contributed to the alveolar septal cell
apoptosis observed in CS-exposed NHPs.
Limitations of the Study
The major limitation of our study is that emphysema did not
develop in CS-exposed NHPs, and it is likely that CS ex-
posures for >12 weeks would be needed to induce emphy-
sema development in NHPs. Also, the pathological changes
observed in NHPs exposed to CS were uniform betweenajp.amjpathol.org - The American Journal of Pathology
Smoke-Induced Airway Disease in NHPsanimals, whereas many human cigarette smokers do not
develop COPD, and in human smokers who develop COPD,
the lung pathologies that develop vary considerably from
patient to patient. Thus, although CS-exposed NHPs are a
better model system of COPD airway disease than CS-
exposed rodents, NHPs still have limitations as a model
system for human COPD. Using NHPs to model CS-induced
airway disease is also expensive because of the high costs
associated with purchasing, housing, and exposing NHPs to
CS. There are also ethical issues associated with animal
research. Recently, research institutions in the United States
have begun the process to limit NHP research activities after
heightened concerns about threats from animal rights activ-
ists directed against scientists performing primate research.69
However, primates can provide unique insights into disease
pathogenesis that cannot be obtained by studying other
organisms.
The advantages of using CS-exposed NHPs over CS-
exposedmice as aCOPDmodel system include the following:
i) the greater genetic, anatomic, histologic, and physiolog-
ical similarities between NHPs and humans compared with
mice and humans; ii) the more robust airway pathologies
than develop in CS-exposed NHPs than CS-exposed mice;
iii) the larger size of NHPs compared with rodents, which
permits serial bronchoscopies and pulmonary function
measurements to be performed safely with techniques and
instruments used in human studies; and iv) serial lung
samples obtained from CS-exposed NHPs may be useful for
biomarker validation studies for early disease detection in
cigarette smokers. The greater similarity between NHPs and
humans may also make CS-exposed NHPs a good model
system for assessing the efﬁcacy (and toxicities) of new
therapies under controlled conditions before clinical trials
are conducted in humans, in whom variable responses are
generally obtained because of differences in ethnicity,
smoking history, drug use, and comorbidities.
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